PHIO

MKT CAP:$14M

Phio Pharmaceuticals Corp.

Market Cap

$14M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.23+$0.14 (+12.84%)

Apr 23, 2026

Company Details

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 ...

CEO

Robert J. Bitterman

IPO Date

May 10, 2012

Website

www.phiopharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$9M

EPS (Diluted)

-$41,071.24

Free Cash Flow

-$8M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 5, 2026

$0EPS -$1.45

Q4 2025

Mar 5, 2026

$0EPS -$0.20

Q3 2025

Nov 13, 2025

$0EPS -$0.44

Q2 2025

Aug 14, 2025

$0EPS -$0.45

Q1 2025

May 15, 2025

$0EPS -$41,070.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$2M	-$3M
Q2 22	$0	-$1M	-$3M
Q3 22	$0	-$3M	-$4M
Q4 22	$0	-$2M	-$3M
Q1 23	$0	-$2M	-$4M
Q2 23	$0	-$49.0K	-$3M
Q3 23	$0	-$2M	-$3M
Q4 23	$0	-$43.0K	-$2M
Q1 24	$0	$0	-$2M
Q2 24	$0	-$866.0K	-$2M
Q3 24	$0	-$644.0K	-$2M
Q4 24	$0	$0	-$2M
Q1 25	$0	$0	-$2M
Q2 25	$0	-$1M	-$2M
Q3 25	$0	-$2.0K	-$3M
Q4 25	$0	-$1.0K	-$3M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$3M	-$4M
Q2 22	-$2M	-$2M
Q3 22	-$4M	-$4M
Q4 22	-$3M	-$3M
Q1 23	-$3M	-$3M
Q2 23	-$3M	-$3M
Q3 23	-$3M	-$3M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$2M	-$2M
Q3 24	-$2M	-$2M
Q4 24	-$1M	-$1M
Q1 25	-$1M	-$1M
Q2 25	-$3M	-$3M
Q3 25	-$2M	-$2M
Q4 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 22	$104.0K
Q2 22	$10.0K
Q3 22	$7.0K
Q4 22	$0
Q1 23	$0
Q2 23	$5.0K
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$1.0K
Q1 25	$2.0K
Q2 25	$3.0K
Q3 25	$7.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-27.4%
Q2 22	—	-6.1%
Q3 22	—	-4.5%
Q4 22	—	-20.9%
Q1 23	—	+36.4%
Q2 23	—	+1.0%
Q3 23	—	-22.3%
Q4 23	—	-35.1%
Q1 24	—	-38.7%
Q2 24	—	-24.9%
Q3 24	—	-42.7%
Q4 24	—	-5.6%
Q1 25	—	-15.3%
Q2 25	—	+20.6%
Q3 25	—	+57.5%
Q4 25	—	+51.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$186.0K	—
Q2 22	$83.0K	—
Q3 22	$103.0K	—
Q4 22	$0	—
Q1 23	$111.0K	—
Q2 23	$94.0K	—
Q3 23	$89.0K	—
Q4 23	$9.0K	—
Q1 24	$32.0K	—
Q2 24	$15.0K	—
Q3 24	$52.0K	—
Q4 24	$48.0K	—
Q1 25	$43.0K	—
Q2 25	$51.0K	—
Q3 25	$113.0K	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$2M	$1M	—
Q2 22	$1M	$1M	—
Q3 22	$3M	$1M	—
Q4 22	$2M	$1M	—
Q1 23	$2M	$1M	—
Q2 23	$1M	$1M	—
Q3 23	$2M	$968.0K	—
Q4 23	$1M	—	$723.0K
Q1 24	$1M	$1M	—
Q2 24	$866.0K	$1M	—
Q3 24	$644.0K	$946.0K	—
Q4 24	$985.0K	—	$689.0K
Q1 25	$886.0K	$986.0K	—
Q2 25	$1M	$1M	—
Q3 25	$1M	—	$1M
Q4 25	$1M	—	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$20M	$0	$20M
Q2 22	$18M	$0	$18M
Q3 22	$14M	$0	$14M
Q4 22	$12M	$0	$12M
Q1 23	$9M	$0	$9M
Q2 23	$11M	$0	$11M
Q3 23	$8M	$0	$8M
Q4 23	$8M	$0	$8M
Q1 24	$6M	$0	$6M
Q2 24	$5M	$0	$5M
Q3 24	$5M	$0	$5M
Q4 24	$5M	$0	$5M
Q1 25	$13M	$0	$13M
Q2 25	$11M	$0	$11M
Q3 25	$11M	$0	$11M
Q4 25	$21M	$0	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	125K	+0.2%	+27.0%
Q2 22	126K	+0.7%	+0.9%
Q3 22	126K	+0.0%	+0.9%
Q4 22	126K	+0.0%	+1.0%
Q1 23	127K	+0.3%	+1.0%
Q2 23	192K	+51.3%	+51.9%
Q3 23	271K	+41.2%	+114.3%
Q4 23	416K	+53.6%	+229.0%
Q1 24	508K	+22.2%	+301.0%
Q2 24	510K	+0.4%	+165.9%
Q3 24	990K	+94.1%	+265.5%
Q4 24	787K	-20.5%	+89.3%
Q1 25	4M	+447.0%	+747.2%
Q2 25	5M	+11.3%	+839.8%
Q3 25	5M	+14.1%	+452.4%
Q4 25	12M	+112.4%	+1375.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	12
Q2 22	$0	12
Q3 22	$0	12
Q4 22	$0	9
Q1 23	$0	9
Q2 23	$0	9
Q3 23	$0	9
Q4 23	$0	8
Q1 24	$0	8
Q2 24	$0	8
Q3 24	$0	8
Q4 24	$0	5
Q1 25	$0	5
Q2 25	$0	5
Q3 25	$0	5
Q4 25	$0	6

Revenue / Employee